By leveraging these advancements, this work demonstrates a streamlined, high-throughput platform for selecting X-aptamers with optimized chemical diversity and enhanced functional performance against CD44, offering potential applications in targeted cancer diagnostics and therapeutics. Here, CD44 is linked to cancer.